Osteoporosis and obesity in men receiving hormone therapy for prostate cancer.
OBJECTIVE
A presentation on osteoporosis, obesity and obesity related disease at the Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment is summarized.


METHODS
A focused literature review was done.


RESULTS
Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density and increase fracture risk. GnRH agonists also increase weight and fat mass, and decrease lean body mass. Treatment related changes in body composition may contribute to fatigue and fracture risk. The phenotype of men with GnRH agonist shares some features with the insulin resistance syndrome, raising the possibility that GnRH may also increase the risk of diabetes mellitus and cardiovascular disease.


CONCLUSIONS
The routine use of GnRH agonists in men with long life expectancy increases the importance of understanding and preventing the unintended adverse effects of treatment. Some adverse effects have the potential to impact not only quality of life, but also noncancer mortality. Additional research is needed to characterize better the unintended effects of androgen deprivation therapy and develop optimal strategies to prevent osteoporosis, obesity and obesity related disease.
Smith
Matthew R
MR
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA. smith.matthew@mgh.harvard.edu
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002136:Calcium, Dietary / Q000009:adverse effects; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000819:agonists* / Q000627:therapeutic use; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D009765:Obesity / Q000453:epidemiology*; D010024:Osteoporosis / Q000453:epidemiology*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology* / Q000503:physiopathology
D018931:Antineoplastic Agents, Hormonal; D002136:Calcium, Dietary; D007987:Gonadotropin-Releasing Hormone